Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Inclusion Criteria: 1. Patients must have unresectable, locally advanced, recurrent disease of esophageal cancer. Histologically confirmed cancer of the esophagus. 2. measurable disease by CT scan 3. ECOG performance status of 0 to 2 4. Expected survival of at least 3months 5. Laboratory values as follow: * Absolute neutrophil count (ANC) ≥ 1.5×109 * White blood cell count ≥ 3×109/L * Platelets ≥ 100×109/L * Haemoglobin (Hb) ≥ 10g/dL (patients'Hb should be corrected to \>10g/dL before treatment) * Adequate liver function (within 1 week prior to randomization) * Serum bilirubin ≤ 1.5× ULN * Alanine aminotransferase/aspartate transaminase (ALT / AST) ≤ 2.5× ULN * Alkaline phosphatase (ALP) ≤ 3× ULN 6. Able and willing to give valid written informed consent Exclusion Criteria: 1. Pregnancy (women of childbearing potential:Refusal or inability to use effective means of contraception) 2. Breastfeeding 3. Active or uncontrolled infection 4. Prior chemotherapy, radiation therapy or immunotherapy 5. Concurrent treatment with steroid or immunosuppressing agent 6. Patient with peptic ulcer disease 7. Other malignancy within 5 years prior to entry into the study, expect for treated non-melanoma skin cancer and cervical carcinoma in situ 8. Disease to the central nervous system 9. Decision of unsuitableness by principal investigator or physician-in-charge